Advertisement

Zusammenfassung

Die Verordnungen von Dermatika halten sich seit Jahren auf stabilem Niveau. Am häufigsten werden Corticosteroide verordnet. Auf sie entfällt 2013 fast die Hälfte der verordneten Tagesdosen aller Dermatika. Deutlich seltener verordnet werden dermatologische Antimykotika (13%), Aknemittel (8%), Psoriasismittel (7%), Antiinfektiva (7%), Warzenmittel (7%) und Wundbehandlungsmittel (6%). Alle übrigen Gruppen hatten einen Verordnungsanteil von unter 5%.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Ågren MS, Ostenfeld U, Kallehave F, Gong Y, Raffn K, Crawford ME, Kiss K, Friis-Møller A, Gluud C, Jorgensen LN (2006): A randomized, double-blind, placebo-controlled multicenter trial evaluating topical zinc oxide for acute open wounds following pilonidal disease excision. Wound Repair Regen 4: 526–535Google Scholar
  2. Alsterholm M, Flytström I, Bergbrant IM, Faergemann J (2010): Fusidic acid-resistant Staphylococcus aureus in impetigo contagiosa and secondarily infected atopic dermatitis. Acta Derm Venereol 90: 52–57PubMedGoogle Scholar
  3. Alston SJ, Cohen BA, Braun M (2003): Persistent and recurrent tinea corporis in children treated with combination antifungal/corticosteroid agents. Pediatrics 111: 201–203PubMedGoogle Scholar
  4. Altmeyer PJ, Matthes U, Pawlak F, Hoffmann K, Frosch PJ, Ruppert P et al. (1994): Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol 30: 977–981PubMedGoogle Scholar
  5. Ammon HPT, Sabieraj J, Kaul R (1996): Kamille. Mechanismus der antiphlogistischen Wirkung von Kamillenextrakten und -inhaltsstoffen. Dtsch Apoth Ztg 136: 1821–1834Google Scholar
  6. Anonymus (2002): New treatments for actinic keratoses. Medical Letter 44: 57–58Google Scholar
  7. Antille C, Saurat JH, Lübbe J (2004): Induction of rosaceiform dermatitis during treatment of facial inflammatory dermatoses with tacrolimus ointment. Arch Dermatol 140: 457–460PubMedGoogle Scholar
  8. Arican O, Sasmaz S, Ozbulu O (2006): Increased suicidal tendency in a case of psoriasis vulgaris under acitretin treatment. J Eur Acad Dermatol Venerol 20: 464–465Google Scholar
  9. Arzneimittelkommission der deutschen Ärzteschaft (1999): Nutzen und Risiken durch Fumarsäure- Ester bei der Therapie der Psoriasis. Dtsch Ärztebl 96: A–721Google Scholar
  10. Arzneimittelkommission der deutschen Ärzteschaft (2005): Myopathie nach Tacrolimus-Salbe (Protopic?). Dtsch Ärztebl 102: A313–8Google Scholar
  11. Arzneimittelkommsission der deutsche Ärzteschaft (2006): Psychiatrische Reaktionen nach Terninafin (Lamisil?). Dtsch Ärztebl 103: A343–2Google Scholar
  12. Arzneimittelkommsission der deutsche Ärzteschaft (2011): Multiple aktinische Keratosen (Carcinomata in situ der Haut) nach langjähriger topischer Anwendung von Tacrolimus (Protopic®). Dtsch Ärztebl 108: A545–A546Google Scholar
  13. Arzneimittelkommsission der deutsche Ärzteschaft (2013a): Rhabdomyolyse nach Isotretinoin. Dtsch Ärztebl 110: A 240.Google Scholar
  14. Arzneimittelkommsission der deutsche Ärzteschaft (2013b): Nokardiose bei Lymphopenie durch Fumaderm® (Aus der UAW-Datenbank). . Dtsch Ärztebl 110: A 1220–1221Google Scholar
  15. Aziz Z, Abu SF, Chong NJ (2012): A systematic review of silver-containing dressings and topical silver agents (used with dressings) for burn wounds. Burns 38: 307–318PubMedGoogle Scholar
  16. Balak DM, Oostveen AM, Bousema MT, Venema AW, Arnold WP, Seyger MM, Thio HB (2013): Effectiveness and safety of fumaric acid esters in children with psoriasis: a retrospective analysis of 14 patients from The Netherlands. Br J Dermatol 168: 1343–1347PubMedGoogle Scholar
  17. Baran R, Kaoukhov A (2005): Topical antifungal drugs fort he treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy. J Eur Acad Dermatol Venerol 19: 21–29Google Scholar
  18. Barker JNWN (2011): Methotrexate or fumarates: which is the best oral treatment for psoriasis? Br J Dermatol 164: 69–5Google Scholar
  19. Bell-Syer SEM, Hart R, Crawford F, Torgerson DJ, Tyrell W, Russell I (2006): Oral treatments for fungal infections of the skin of the foot (Cochrane Review). In: The Cochrane Library, Issue 1 2006. Oxford: Update SoftwareGoogle Scholar
  20. Berrios RL, Arbiser JL (2011): Effectiveness of gentian violet and similar products commonly used to treat pyodermas. Dermatol Clin 29: 69–73PubMedGoogle Scholar
  21. Berth-Jones J, Damstra RJ, Golsch S, Livden JK, Van Hooteghem O, Allegra F, Parker CA. Multinational Study Group (2003): Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double- blind, parallel group study. Brit Med J 326: 1367–1373Google Scholar
  22. Bewley A for the Dermatology Working Group (2008): Expert consensus: time for a change in the way we advise our patients to use topical corticosteroids. Br J Dermatol 158: 917–920Google Scholar
  23. Biogen Idec GmbH (2013): Wichtige Hinweise an medizinische Fachkreise: Fumaderm® initial / Fumaderm® – Vermeidung des Risikos opportunistischer Infektionen durch Einhaltung regelmäßiger Laborkontrollen und weiterer Warnhinweise während der Therapie. http://www.akdae.de/Arzneimittelsicherheit/RHB/20130625.pdf
  24. Biro K, Thaci D, Ochsendorf FR, Kaufmann R, Boehncke W-H (2003): Efficacy of dexpanthenol in skin protection against irritation: a double-blind, placebo-controlled study. Contact Dermatitis 49: 80–84PubMedGoogle Scholar
  25. Boguniewicz M, Leung DY (2010): Recent insights into atopic dermatitis and implications for management of infectious complications. J Allergy Clin Immunol 125: 4–13PubMedGoogle Scholar
  26. Booij MT, van De Kerkhof PC (2011): Acitretin revisited in the era of biologics. J Dermatolog Treat 22: 86–89PubMedGoogle Scholar
  27. Bradley M, Cullum N, Sheldon T (1999): The debridement of chronic wounds: a systematic review. Health Technol Assess 3: 1–78Google Scholar
  28. Braun R (Hrsg.) (2014): Arzneistoff-Profile, Basisinformation über arzneilich wirksame Wirkstoffe. Stammlieferung 1982 mit 1. bis 27. Erg.-Lieferung 2014, Govi-Verlag Pharmazeutischer Verlag GmbH, EschbornGoogle Scholar
  29. Braun-Falco O, Plewig G, Wolff HH, Burgdorf WHC, Landthaler M (2005): Dermatologie und Venerologie, 5. Auflage. Springer Medizin Verlag, HeidelbergGoogle Scholar
  30. Bristow IR, Baran R (2006): Topical and oral combination therapy for toenail onychomycosis. An updated review. J Am Podiatr Med Associat 96: 116–119Google Scholar
  31. Bundesinstitut für Arzneimittel und Medizinprodukte (2013): Informationsbrief zu oralen ketoconazolhaltigen Arzneimitteln (Nizoral® Tabletten): Ruhen der Zulassung wegen schwerer Leberschädigungen. http://www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/DE/RHB/2013/info-nizoral.html
  32. Bundesministerium für Gesundheit und Soziale Sicherung (2004): Bekanntmachung des Gemeinsamen Bundesausschusses über eine Änderung der Richtlinien über die Verordnung von Arzneimitteln in der vertragsärztlichen Versorgung (Arzneimittel-Richtlinien) vom 15. Juni 2004. BAnz. Nr. 156 (S. 18 661) vom 20.08.2004, https://www.g-ba.de/institution/sys/suche/ergebnis/?suche[suchbegriff]=crinohermal&suche[offset]=0&suche[sortierung]=relevanz&suche[kategorie]=alle
  33. Calow T, Oberle K, Bruckner-Tuderman L, Jakob T, Schumann H (2009): Contact dermatitis due to use of Octenisept(R) in wound care. J Dtsch Dermatol Ges 7: 759–765PubMedGoogle Scholar
  34. Casciano J, Amaya K, Doyle J, Arikian S, Shear N, Haspel M, Kahler K (2003): Economic analysis of oral and topical therapies for onychomycosis of the toenails and fingernails. Manag Care 12: 47–54PubMedGoogle Scholar
  35. Chen SL, Yan J, Wang FS (2010): Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials. J Dermatolog Treat 21: 144–156PubMedGoogle Scholar
  36. Christiansen B (1988): Untersuchungen über die Wirksamkeit eines Hautdesinfektionsmittels mit kationenaktivem Zusatz. Zbl Bakt Hyg B 186: 368–374Google Scholar
  37. Chroni E, Monastirli A, Tsambaos D (2010): Neuromuscular adverse effects associated with systemic retinoid dermatotherapy: monitoring and treatment algorithm for clinicians. Drug Saf 33: 25–34PubMedGoogle Scholar
  38. Conde JF, Yelverton CB, Balkrishnan R, Fleischer AB Jr, Feldman SR (2007): Managing rosacea: a review of the use of metronidazole alone and in combination with oral antibiotics. J Drugs Dermatol 6: 495–498PubMedGoogle Scholar
  39. Crawford F, Young P, Godfrey C, Bell-Syer SEM, Hart R, Brunt E, Russel I (2002): Oral treatments for toenail onychomycosis. Arch Dermatol 138: 811–816PubMedGoogle Scholar
  40. Crawford F, Hollis S (2007): Topical treatments for fungal infections of the skin and nails of the foot. Cochrane Database Syst Rev 2007 Jul 18 (3): CD00143–4Google Scholar
  41. Cunningham A, Griffiths P, Leone P, Mindel A, Patel R, Stanberry L, Whitley R (2012): Current management and recommendations for access to antiviral therapy of herpes labialis. J Clin Virol 53: 6–11PubMedCentralPubMedGoogle Scholar
  42. Dall’oglio F, D’Amico V, Nasca MR, Micali G (2012): Treatment of cutaneous warts: an evidence- based review. Am J Clin Dermatol 13: 73–96PubMedGoogle Scholar
  43. Darkes MJM, Scott LJ, Goa KL (2003): Terbinafine. A review of its use in onychomycosis in adults. Am J Clin Dermatol 4: 39–65PubMedGoogle Scholar
  44. Del Rosso JQ, Pillai R, Moore R (2010): Absence of degradation of tretinoin when benzoyl peroxide is combined with an optimized formulation of tretinoin gel (0.05%). J Clin Aesthet Dermatol 3: 26–28PubMedCentralPubMedGoogle Scholar
  45. Deutsche Dermatologische Gesellschaft (2009a): Topische Dermatotherapie mit Glukokortikoiden – Therapeutischer Index. AWMF-Leitlinien-Register Nr. 013/034, http://www.awmf.org/uploads/tx_szleitlinien/013-034.pdf
  46. Deutsche Dermatologische Gesellschaft (2009b): Psoriasis des behaarten Kopfes. AWMF-Leitlinien- Register Nr. 013/074, http://www.awmf.org/uploads/tx_szleitlinien/013-074.pdf
  47. Deutsche Dermatologische Gesellschaft (2011a): Leitlinie zur Therapie der Psoriasis vulgaris – Update 2011. AWMF-Leitlinien-Register Nr. 013/001, http://www.awmf.org/uploads/tx_szleitlinien/013-001l_S3_Psoriasis_vulgaris_Therapie_01.pdf
  48. Deutsche Dermatologische Gesellschaft (2011b): Behandlung der Akne. AWMF-Leitlinien- Register Nr. 013/017, www.awmf.org/uploads/tx_szleitlinien/013-017l_S2k_Behandlung_der_Akne_2011-10-Korrektur.pdf
  49. Deutsche Dermatologische Gesellschaft (2011c): Leitlinie zur Behandlung der aktinischen Keratosen C44.X. AWMF-Leitlinien-Register Nr. 013/041, http://www.awmf.org/uploads/tx_szleitlinien/013-041l_S1_Aktinische_Keratose_2012-01.pdf
  50. Deutsche Dermatologische Gesellschaft, Berufsverband Deutscher Dermatologen (2009): Therapie des atopischen Ekzems mit Calcimeurin-Inhibitoren. AWMF-Leitlinien-Register Nr. 013/037, http://www.awmf.org/uploads/tx_szleitlinien/013-037.pdf
  51. Deutsche Dermatologische Gesellschaft, Deutschsprachige Mykologische Gesellschaft (2008): Tinea der freien Haut. AWMF-Leitlinien-Register Nr. 013-002, http://www.awmf.org/uploads/tx_szleitlinien/013-002.pdf
  52. Deutsche Dermatologische Gesellschaft (DDG) et al (2008): Neurodermitis, AWMF-Leitlinien- Register Nr. 013/027, http://www.awmf.org/uploads/tx_szleitlinien/013-027l_S2e_Neurodermitis_01.pdf
  53. Deutsche Gesellschaft für Phlebologie (2008): Diagnostik und Therapie des Ulcus cruris venosum. AWMF-Leitlinien-Register Nr. 037/009, http://www.awmf.org/uploads/tx_szleitlinien/037-009_S3_Diagnostik_und_Therapie_des_Ulcus_cruris_venosum_lang_08-2008_08-2013.pdf
  54. Dissemond J, Gerber V, Kramer A, Riepe G, Strobal R, Vasel-Biergans A, Eberlein T (2009): Praxisorientierte Empfehlung zur Behandlung kritisch-kolonisierter und lokal infizierter Wunden mit Polihexanid. Wundmanagement 3: 62–68Google Scholar
  55. Dissemond J, Augustin M, Eming SA, Goerge T, Horn T, Karrer S., Schumann H, Stücker M, for the working group for wound healing (AGW) of the German Society of Dermatology (DDG) (2014): Modern wound care – practical aspects of non-interventional topical treatment of patients with chronic wounds. J Dtsch Ges Dermatol, published online: 12 May 2014, DOI: 10.1111/ddg.12351, http://onlinelibrary.wiley.com/doi/10.1111/ddg.12351/pdf
  56. Dobie D, Gray J (2004): Fusidic acid resistance in Staphylococcus aureus. Arch Dis Child 89: 74–77PubMedCentralPubMedGoogle Scholar
  57. Drake LA, Dinehart SM, Farmer ER, Goltz RW, Graham GF, Hordinsky MK, Lewis CW, Pariser DM, Webster SB, Whitaker DC, Butler B, Lowery BJ, Raimer SA, Krafchik BR, Olsen E, Weston WL (1996): Guidelines of care for the use of topical glucocorticosteroids. American Academy of Dermatology. J Am Acad Dermatol 35: 615–619PubMedGoogle Scholar
  58. Drucker CR (2012): Update on topical antibiotics in dermatology. Dermatol Ther 25: 6–11PubMedGoogle Scholar
  59. Eberlein T, Assadian O (2010): Clinical use of polihexanide on acute and chronic wounds for antisepsis and decontamination. 23 (Suppl): 45–51Google Scholar
  60. Eberlein T, Haemmerle G, Signer M, Gruber Moesenbacher U, Traber J, Mittlboeck M, Abel M, Strohal R (2012): Comparison of PHMB-containing dressing and silver dressings in patients with critically colonised or locally infected wounds. J Wound Care 21: 12–20Google Scholar
  61. Ebner F, Heller A, Rippke F, Tausch I (2002): Topical use of dexpanthenol in skin disorders. Am J Clin Dermatol 3: 427–433PubMedGoogle Scholar
  62. Eckhard M, Lengler A, Liersch J, Bretzel RG, Mayser P (2007): Fungal foot infections in patients with diabetes mellitus – results of two independent investigations. Mycoses 50 (Suppl 2): 14–19PubMedGoogle Scholar
  63. Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, Bergman JN, Chamlin SL, Cohen DE, Cooper KD, Cordoro KM, Davis DM, Feldman SR, Hanifin JM, Margolis DJ, Silverman RA, Simpson EL, Williams HC, Elmets CA, Block J, Harrod CG, Begolka WS, Sidbury R (2014): Guidelines of care for the management of atopic dermatitis: Section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol 2014 May 7. pii: S0190-9622(14)01257–2. doi: 10.1016/j.jaad.2014.03.023. [Epub ahead of print]Google Scholar
  64. Eifler-Bollen R, Fluhr JW (2005): Antimikrobiell wirksame Magistralrezepturen. Stellenwert in der Praxis und kritische Anmerkungen. Hautarzt 56: 752–758PubMedGoogle Scholar
  65. El Sayed F, Ammoury A, Dhaybi R, Bazex J (2006): Rosaceiform eruption to pimecrolimus. J Am Acad Dermatol 54: 548–550PubMedGoogle Scholar
  66. Ermis U, Weis J, Schulz JB (2013): PML in a patient treated with fumaric acid. N Engl J Med 368: 1657–1658PubMedGoogle Scholar
  67. Erbagci Z (2004): Topical therapy for dermatophytoses. Should corticosteroids be included? Am J Clin Dermatol 5: 375–384PubMedGoogle Scholar
  68. European Medicines Agency (EMA) (2006): European Medicines Agency recommends cautious use of Protopic/Protopy and Elidel. http://www.emea.europa.eu/pdfs/general/direct/pr/9888206en.pdf
  69. Fallah Arani S, Neumann H, Hop WC, Thio HB (2011): Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial. Br J Dermatol 164:855–861PubMedGoogle Scholar
  70. Fallen RS, Gooderham M (2012): Rosacea: update on management and emerging therapies. Skin Therapy Lett 17: 1–4PubMedGoogle Scholar
  71. FDA Center for Drug Evaluation and Research, Office of Surveillance and Epidemiology (2010): Topical calcineurin inhibitors: Literature review. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM255139.pdf
  72. FDA Center for Drug Evaluation and Research, Office of Surveillance and Epidemiology (2011): Topical calcineurin inhibitors: Literature review addendum. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM255140.pdf
  73. Ference JD, Last AR (2009): Choosing topical corticosteroids. Am Fam Physician 79: 135–140PubMedGoogle Scholar
  74. Fleischer AB jr, Abramovits W, Breneman D, Jaracz E; US/Canada tacrolimus ointment study group (2007): Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis. J Dermatol Treat 18: 151–157Google Scholar
  75. Fleischer AB, Feldman SR (1999): Prescription of high-potency corticosteroid agents and clotrimazole- betamethasone dipropionate by pediatricians. Clin Ther 10: 1725–1731Google Scholar
  76. Fluhr JW, Cavallotti C, Berardesca E (2008): Emollients, moisturizers, and keratolytic agents in psoriasis. Clin Dermatol 26: 380–386PubMedGoogle Scholar
  77. Fluhr JW, Degitz K (2010): Antibiotika, Azelainsäure und Benzoylperoxid in der topische Aknetherapie. J Dtsch Dermatol Ges 8 (Suppl 1): S24–30PubMedGoogle Scholar
  78. Fölster-Holst R, Latussek E (2007): Synthetic tannins in dermatology – a therapeutic option in a variety of pediatric dermatoses. Pediatr Dermatol 24: 296–301PubMedGoogle Scholar
  79. Food and Drug Adminstration (2005): Elidel (pimecrolimus) Cream and Protopic (tacrolimus) Ointment. http://www.fda.gov/cder/drug/advisory/elidel_protopic.htm
  80. Food and Drug Adminstration (2014): FDA warns of rare but serious hypersensitivity reactions with certain over-the-counter topical acne products. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM402663.pdf
  81. Frankel HC, Qureshi AA (2012): Comparative effectiveness of topical calcineurin inhibitors in adult patients with atopic dermatitis. Am J Clin Dermatol 13: 113–123PubMedGoogle Scholar
  82. Franz T, Vögelin E (2012): Aseptic tissue necrosis and chronic inflammation after irrigation of penetrating hand wounds using Octenisept®. J Hand Surg Eur 37: 61–64Google Scholar
  83. Friese K, Neumann G, Siebert J (2003): Topical antiseptics as an alternative in the treatment of acute vulvovaginal candidosis. Arch Gynecol Obstet 268: 194–197PubMedGoogle Scholar
  84. Garnock-Jones KP, Perry CM (2009): Alitretinoin: in severe chronic hand eczema. Drugs 69: 1625–1634PubMedGoogle Scholar
  85. Gaspari A, Tyring SK, Rosen T (2009): Beyond a decade of 5% imiquimod topical therapy. J Drugs Dermatol 8: 467–474Google Scholar
  86. Gemeinsamer Bundesausschuss (2014): Richtlinie des Gemeinsamen Bundesausschusses über die Verordnung von Arzneimitteln in der vertragsärztlichen Versorgung (Arzneimittel- Richtlinie/AM-RL) in der Fassung vom 18. Dezember 2008/22. Januar 2009, veröffentlicht im Bundesanzeiger 2009, Nr. 49a, zuletzt geändert am 20. März 2014 veröffentlicht BAnz AT 05.05.2014 B2 in Kraft getreten am 6. Mai 2014 https://www.g-ba.de/downloads/62-492-871/AM-RL_2014-03-20_iK-2014-05-06.pdf
  87. Gibbs S, Harvey I (2006): Topical treatments for cutaneous warts. Cochrane Database of Systematic Reviews 2006, Issue 3. Art. No.: CD001781. DOI: 10.1002/14651858.CD001781.pub2.PubMedGoogle Scholar
  88. Glenn CJ, Kobraei KB, Russo JJ (2011): New-onset psoriasis associated with adalimumab: a report of two cases. Dermatol Online J 17: 1–5Google Scholar
  89. Gloor M (1982): Pharmakologie dermatologischer Externa. Springer-Verlag, Berlin Heidelberg New YorkGoogle Scholar
  90. Gollnick H, Altmeyer P, Kaufmann R, Ring J, Christophers E, Pavel S, Ziegler J (2002): Topical calcipotriol plus oral fumaric acid is more effective and faster acting than oral fumaric acid monotherapy in the treatment of severe chronic plaque psoriasis vulgaris. Dermatology 205: 46–53PubMedGoogle Scholar
  91. González U, Seaton T, Bergus G, Jacobson J, Martínez-Monzón C (2007): Systemic antifungal therapy for tinea capitis in children. Cochrane Database Syst Rev. 2007, Issue 4. Art. No.: CD004685. DOI: 10.1002/14651858.CD004685.pub2PubMedGoogle Scholar
  92. Gorman CR, White SW (2005): Rosaceiform dermatitis as a complication of treatment of facial seborrhoic dermattis with 1% pimecrolimus cream. Arch Dermatol 141: 116–8Google Scholar
  93. Griffiths CE, Barker JN (2007): Pathogenesis and clinical features of psoriasis. Lancet 370: 263–271PubMedGoogle Scholar
  94. Grover C, Arora P, Manchanda V (2012): Comparative evaluation of griseofulvin, terbinafine und fluconazole in the trteatment of tinea capitis. Int J Dermatol 51: 455–458PubMedGoogle Scholar
  95. Grover C, Khurana A (2012): An update on treatment of onychomycosis. Mycoses 55: 541–551PubMedGoogle Scholar
  96. Gupta AK (2002): Treatment of dermatophyte toenail onychomycosis in the United States. A pharmacoeconomic analysis. J Am Pediatr Med Assoc 92: 272–286Google Scholar
  97. Gupta AK, Cherman AM, Tyring SK (2005): Viral and nonviral uses of imiquimod: A review. J Cut Med Surg 8: 338–352Google Scholar
  98. Gupta AK, Cooper EA (2008): Update in antifungal therapy of dermatophytosis. Mykopathologia 166: 353–367Google Scholar
  99. Gupta AK, Cooper EA, Ryder JE, Nicol KA, Chow M, Chaudhry MM (2004): Optimal management of fungal infections of the skin, hair, and nails. Am J Clin Dermatol 5: 225–237PubMedGoogle Scholar
  100. Hahn C, Röseler S, Fritzsche R, Schneider R, Merk HF (1993): Allergic contact reaction to dexpanthenol: lymphocyte transformation test and evidence for microsomal-dependent metabolism of the allergen. Contact Dermatitis 28: 81–83PubMedGoogle Scholar
  101. Haugh M, Helou S, Boissel JP, Cribier BJ (2002): Terbinafine in fungal infections of the nails: a meta-analysis of randomized clinical trials. Br J Dermatol 147: 118–121PubMedGoogle Scholar
  102. Hauschild A, Kähler KC, Egberts F (2006): Moderne Behandlungsoptionen bei aktinischen Keratosen der Haut. Dtsch Med Wochenschr 131: 447–452PubMedGoogle Scholar
  103. Hendriks AG, Keijsers RR, de Jong EM, Seyger MM, van de Kerkhof PC (2013a): Combinations of classical time-honoured topicals in plaque psoriasis: a systematic review. J Eur Acad Dermatol Venereol 27:399–410Google Scholar
  104. Hendriks AG, Keijsers RR, de Jong EM, Seyger MM, van de Kerkhof PC (2013b): Efficacy and safety of combinations of first-line topical treatments in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol 27:931–951Google Scholar
  105. Hengge UR, Ruzicka T, Schartz RA, Cork MJ (2006): Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 54: 1–15PubMedGoogle Scholar
  106. Hoefnagel JJ, Thio HB, Willemze R, Bouwes Bavinck JN (2003): Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br J Dermatol 149: 363–369PubMedGoogle Scholar
  107. Hoffmann R, Happle R (2000): Current understanding of androgenetic alopecia. Part II: clinical aspects and treatment. Eur J Dermatol 10: 410–417PubMedGoogle Scholar
  108. Hornstein OP, Nürnberg E (Hrsg) (1985): Externe Therapie von Hautkrankheiten. Pharmazeutische und medizinische Praxis. Georg Thieme Verlag, Stuttgart New YorkGoogle Scholar
  109. Hund M, Sinkgraven R, Rzany B (2004): Randomisierte, plazebokontrollierte klinische Doppelblindstudie zur Wirksamkeit und Verträglichkeit der oralen Therapie mit Methantheliniumbromid (Vagantin?) bei fokaler Hyperhidrose. J Dtsch Dermatol Ges 2: 43–349Google Scholar
  110. Iorizzo M, Piraccini BM, Tosti A (2010): Today's treatments options for onychomycosis. J Dtsch Dermatol Ges 8: 875–879PubMedGoogle Scholar
  111. Jarvis B, Figgitt DP (2003): Topical 3% diclofenac in 2.5% hyaluronic acid gel. A review of its use in patients with actinic keratoses. Am J Clin Dermatol 4: 203–213PubMedGoogle Scholar
  112. Johnson MR, Hageboutros A, Wang K, High L, Smith JB, Diasio RB (1999): Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res 5: 2006–2011PubMedGoogle Scholar
  113. Kakourou T, Uksal U; European Society for Pediatric Dermatology (2010): Guidelines for the management of tinea capitis in children. Pediatr Dermatol 27: 226–228PubMedGoogle Scholar
  114. Kalavala M, Dohil MA (2011): Calcineurin inhibitors in pediatric atopic dermatitis: a review of current evidence. Am J Clin Dermatol 12: 15–24PubMedGoogle Scholar
  115. Komericki P, Akkilic-Materna M, Strimitzer T, Aberer W (2011): Efficacy and safety of imiquimod versus podophyllotoxin in the treatment of anogenital warts. Sex Transm Dis 38: 216–218PubMedGoogle Scholar
  116. Koning S, van der Sande R, Verhagen AP, van Suijlekom-Smit LWA, Morris AD, Butler CC, Berger M, van der Wouden JC (2012): Interventions for impetigo. Cochrane Database of Systematic Reviews 2012, Issue 1. Art. No.: CD003261. DOI: 10.1002/14651858.CD003261.pub3PubMedGoogle Scholar
  117. Koo JYM (2005): New developments in topical sequential therapy for psoriasis. Skin Therapy Lett 10: 1–4PubMedGoogle Scholar
  118. Korting HC (1995): Dermatotherapie: ein Leitfaden. Springer-Verlag, Berlin Heidelberg New YorkGoogle Scholar
  119. Korting HC, Schäfer-Korting M., Klövekorn W., Klövekorn G., Martin C., Laux P (1995): Comparative efficacy of hamamelis distillate and hydrocortisone cream in atopic eczema. Eur J Clin Pharmacol 48: 461–465PubMedGoogle Scholar
  120. Krug M, Oji V, Traupe H, Berneburg M (2009): Ichthyoses – Part 1: Differential diagnosis of vulgar ichthyoses and therapeutic options. J Dtsch Dermatol Ges 7: 511–519PubMedGoogle Scholar
  121. Küster W, Bohnsack K, Rippke F, Upmeyer HJ, Groll S, Traupe H (1998): Efficacy of urea therapy in children with ichthyosis. A multicenter randomized, placebo-controlled, double-blind, semilateral study. Dermatology 196: 217–222PubMedGoogle Scholar
  122. Küster W (2006): Ichthyosen: Vorschläge für eine verbesserte Therapie. Dtsch Ärztebl 103: A1684–A1689Google Scholar
  123. Kujath P, Michelsen A (2008): Wunden – von der Physiologie zum Verband. Dtsch Ärztebl 105: 239–248Google Scholar
  124. Kwok CS, Gibbs S, Bennen C, Holland R, Abbott R (2012): Topical treatments for cutaneous warts, Cochrane Database o(Systematic Reviews 2012, Issue 9, Art, No« CD00178L DOr: 10,1002/14651858,CD00178Lpub3Google Scholar
  125. Lachapelle JM (2014): A comparison of the irritant and allergenic properties of antiseptics. Eur J Dermatol 24: 3–9PubMedGoogle Scholar
  126. Lakshmi C, Srinivas CR (2012): Hand eczema: An update. Indian J Dermatol Venereol Leprol 78: 569–582PubMedGoogle Scholar
  127. Langer A, Rogowski W (2009): Systematic review of economic evaluations of human cell-derived wound care products for the treatment of venous leg and diabetic foot ulcers. BMC Health Services Research 2009, 9: 115 (doi:10.1186/1472-6963-9-115)PubMedCentralPubMedGoogle Scholar
  128. Langner A, Sheehan-Dare R, Layton A (2007): A randomized, single-blind comparison of topical clindamycin + benzoyl peroxide (Duac) and erythromycin + zinc acetate (Zineryt) in the treatment of mild to moderate facial acne vulgaris. J Eur Acad Dermatol Venereol 21: 311–319PubMedGoogle Scholar
  129. Lansdown AB, Mirastschijski U, Stubbs N, Scanlon E, Ågren MS (2007): Zinc in wound healing: theoretical, experimental, and clinical aspects. Wound Repair Regen 15: 2–16PubMedGoogle Scholar
  130. Lecha M, Effendy I, Feuilhade de Chauvin M, Di Chiacchio N, Baran R (2005): Treatment options – development of consensus guidelines. J Eur Acad Dermatol Venereol 19 (suppl 1): 25–33PubMedGoogle Scholar
  131. Lee S, Selva D, Huilgol SC, Goldberg RA, Leibovitch I (2007): Pharmacological treatments for basal cell carcinoma. Drugs 67: 915–934PubMedGoogle Scholar
  132. Lohde H, Stahlmann R (Hrsg.) (2004): Nadifloxacin – irrationaler Einsatz eines Fluorchinolons zur lokalen Aknetherapie. Zeitschr Chemother 25: 27–29Google Scholar
  133. Løkkevik E, Skovlund E, Reitan JB, Hannisdal E, Tanum G (1996): Skin treatment with Bepanthen cream versus no cream during radiotherapy. Acta Oncol 35: 1021–1026PubMedGoogle Scholar
  134. Longstaff E, von Krogh G (2001): Condyloma eradication: self-therapy with 0.15–0.5% podophyllotoxin versus 20–25% podophyllin preparations–an integrated safety assessment. Regul Toxicol Pharmacol 33: 117–137PubMedGoogle Scholar
  135. Lopaschuk CR (2013): New approach to managing genital warts. Can Fam Physician 59: 731– 736PubMedCentralPubMedGoogle Scholar
  136. Magin P, Sullivan J (2010): Suicide attempts in people taking isotretinoin for acne. Br Med J 341: c5866Google Scholar
  137. Maiche AG, Gröhn P, Mäki-Hokkonen H (1991): Effect of chamomile cream and almond ointment on acute radiation skin reaction. Acta Oncol 30: 395–396PubMedGoogle Scholar
  138. Mahil SK, Andrews TC, Brierley C, Barker JN, Smith CH (2013): Demyelination during tumour necrosis factor antagonist therapy for psoriasis: a case report and review of the literature. J Dermatolog Treat 24: 38–49PubMedGoogle Scholar
  139. Mayser P, Freund V, Budihardja D (2009): Toenail onychomycosis in diabetic patients: issues and managemant. Am J Clin Dermatol 10: 211–220PubMedGoogle Scholar
  140. McClellan KJ, Noble S (2000): Topical metronidazole. A review of its use in rosacea. Am J Clin Dermatol 1: 191–199PubMedGoogle Scholar
  141. McNeil JC, Hulten KG, Kaplan SL, Mason EO (2014): Decreased susceptibilities to Retapamulin, Mupirocin, and Chlorhexidine among Staphylococcus aureus isolates causing skin and soft tissue infections in otherwise healthy children. Antimicrob Agents Chemother 58: 2878–2883PubMedCentralPubMedGoogle Scholar
  142. McIntyre WJ, Downs MR, Bedwell SA (2007): Treatment options for actinic keratoses. Am Fam Physician 76: 667–671PubMedGoogle Scholar
  143. Menezes de Padua CA, Schnuch A, Nink K, Pfahlberg A, Uter W (2008): Allergic contact dermatitis to topical drugs – epidemiological risk assessment. Pharmacoepidemiol Drug Saf 17: 813–821Google Scholar
  144. Merk HF (2007): Topical diclofenac in the treatment of actinic keratoses. Int J Dermatol 46: 12–18PubMedGoogle Scholar
  145. Möhrenschlager M, Seidl HP, Ring J, Abeck D (2005): Pediatric tinea capitis. Recognition and management. Am J Clin Dermatol 6: 203–213PubMedGoogle Scholar
  146. Moore AY (2009): Clinical applications for topical 5-fluorouracil in the treatment of dermatological disorders. J Dermatolog Treat 20: 328–335PubMedGoogle Scholar
  147. Moore ZEH, Cowman S (2013): Wound cleansing for pressure ulcers. Cochrane Database Syst Rev. 2013, Issue 3: CD00498–3. doi: 10.1002/14651858.CD004983.pub3Google Scholar
  148. Mosti G (2013): Wound care in venous ulcers. Phlebology 28 (Suppl 1): 79–85PubMedGoogle Scholar
  149. Müller G, Kramer A (2008): Biocompatibility index of antiseptic agents by parallel assessment of antimicrobial activity and cellular cytotoxicity. Antimicrob Chemother 61: 1281–1287Google Scholar
  150. Muller A, Talon D, Potier A, Belle E, Cappelier G, Bertrand X (2005): Use of intranasal mupirocin to prevent methicillin-resistant Staphylococcus aureus infection in intensive care units. Critical Care 9: R246–R250PubMedCentralPubMedGoogle Scholar
  151. Naldi L, Griffiths CEM (2005): Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol 152: 597–615PubMedGoogle Scholar
  152. Niedner R (1998): Kortikoide in der Dermatologie. UNI-MED Verlag, BremenGoogle Scholar
  153. Niedner R, Ziegenmeyer J (Hrsg) (1992): Dermatika. Therapeutischer Einsatz, Pharmakologie und Pharmazie. Wissenschaftliche Verlagsgesellschaft, StuttgartGoogle Scholar
  154. Palfreyman S, Nelson EA, Michaels JA (2007): Dressings for venous leg ulcers: systematic review and mety-analysis. Br Med J 335: 244–248Google Scholar
  155. Paller AS, Lebwohl M, Fleischer AB jr, Antaya R, Langley RG, Kirsner RS, Blum RR, Rico MJ, Jaracz E, Crowe A, Linowski GJ; US/Canada Tacrolimus Ointment Study Group (2005): Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. J Am Acad Dermatol 52: 810–822Google Scholar
  156. Pariser DM, Bagel J, Gelfand JM, Korman NJ, Ritchlin CT, Strober BE, Van Voorhees AS, Young M, Rittenberg S, Lebwohl MG, Horn EJ, for the Psoriasis Foundation (2007): National Psoriasis Foundation clinical consensus on disease severity. Arch Dermatol 143: 239–242PubMedGoogle Scholar
  157. Patel B, Siskin S, Krazmien R, Lebwohl M (1998): Compatibility of calcipotriene with other topical medications. J Am Acad Dermatol 38: 1010–1011PubMedGoogle Scholar
  158. Patel R, Alderson S, Geretti A, Nilsen A, Foley E, Lautenschlager S, Green J, van der Meijden W, Gomberg M, Moi H; IUSTI/WHO Europe (2011): European guideline for the management of genital herpes, 2010. Int J STD AIDS 22: 1–10.PubMedGoogle Scholar
  159. Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, Barker J, Bos JD, Burmester GR, Chimenti S, Dubertret L, Eberlein B, Erdmann R, Ferguson J, Girolomoni G, Gisondi P, Giunta A, Griffiths C, Hönigsmann H, Hussain M, Jobling R, Karvonen SL, Kemeny L, Kopp I, Leonardi C, Maccarone M, Menter A, Mrowietz U, Naldi L, Nijsten T, Ortonne JP, Orzechowski HD, Rantanen T, Reich K, Reytan N, Richards H, Thio HB, van de Kerkhof P, Rzany B (2009): European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 23 (Suppl 2): 1–70PubMedGoogle Scholar
  160. Peserico A, Städtler G, Sebastian M, Fernandez RS, Vick K, Bieber T (2008): Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study. Br J Dermatol 158: 801–807PubMedGoogle Scholar
  161. Piatkowski A, Drummer N, Andriessen A, Ulrich D, Pallua N (2011): Randomized controlled single center study comparing a polyhexanide containing bio-cellulose dressing with silver sulfadiazine cream in partial-thickness dermal burns. 37: 800–804Google Scholar
  162. Post B, Jänner M (1971): Zur Indikation der Gerbstofftherapie in der Dermatologie. Klinische Erfahrungen mit Tannosynt. Ther Ggw 110: 1477–1494PubMedGoogle Scholar
  163. Psoriasis-Netzwerk (2014): Tarmed® Teer-Shampoo kommt nicht vor 2016 zurück. Internet: http://www.psoriasis-netz.de/medikamente/allgemein/tarmedr-teer-shampoo-nicht-vor-2016.html
  164. Qureshi AA, Fischer MA (2006): Topical calcineurin inhibitors for atopic dermatitis - Balancing clinical benefit and possible risks. Arch Dermatol 142: 633–637PubMedGoogle Scholar
  165. Rahimi H, Mara T, Costella J, Speechley M, Bohay R (2012): Effectiveness of antiviral agents for the prevention of recurrent herpes labialis: a systematic review and meta-analysis. Oral Surg Oral Med Oral Pathol Oral Radiol 113: 618–627PubMedGoogle Scholar
  166. Ramos-e-Silva M, Oliveira Lima CM, Casz Schechtman R, Moritz Trope B, Carneiro S (2012): Systemic mycoses in immunodepressed patients (AIDS) Clin Dermatol 30: 616–627PubMedGoogle Scholar
  167. Rathi SK, D’Souza P (2012): Rational and ethical use of topical corticosteroids based on safety and efficacy. Indian J Dermatol 57: 251–259PubMedCentralPubMedGoogle Scholar
  168. Ring J, Fröhlich HH (1985): Wirkstoffe in der dermatologischen Therapie, 2. Aufl, Springer- Verlag, Berlin HeidelbergGoogle Scholar
  169. Rotta I, Sanchez A, Gonçalves PR, Otuki MF, Correr CJ (2012): Efficacy and safety of topical antifungals in the treatment of dermatomycosis: a systematic review. Br J Dermatol 166: 927–933PubMedGoogle Scholar
  170. Ruzicka T (2006): Methylprednisolone aceponate in eczema and other inflammatory skin disorders – a clinical update. Int J Clin Pract 60: 85–92PubMedGoogle Scholar
  171. Ruzicka T, Lynde CW, Jemec GB, Diepgen T, Berth-Jones J, Coenraads PJ, Kaszuba A, Bissonnette R, Varjonen E, Holló P, Cambazard F, Lahfa M, Elsner P, Nyberg F, Svensson A, Brown TC, Harsch M, Maares J (2008): Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. Br J Dermatol 158: 808–817PubMedGoogle Scholar
  172. Samrao A, Cockerell CJ (2013): Pharmacotherapeutic management of actinic keratosis: focus on newer topical agents. Am J Clin Dermatol 14: 273–237Google Scholar
  173. Sapijaszko MJA (2005): Imiquimod 5% cream (Aldara®) in the treatment of basal cell carcinoma. Skin Ther Lett 10: 2–5Google Scholar
  174. Schäfer-Korting M, Schmid MH, Korting HC (1996): Topical glucocorticoids with improved risk-benefit ratio. Drug Safety 14: 375–385PubMedGoogle Scholar
  175. Schlievert PM, Strandberg KL, Lin YC, Peterson ML, Leung DY (2010): Secreted virulence factor comparison between methicillin-resistant and methicillin-sensitive Staphylococcus aureus, and its relevance to atopic dermatitis. J Allergy Clin Immunol 125: 39–49PubMedGoogle Scholar
  176. Schneider LA, Hinrichs R, Scharfetter-Kochanek K (2007): Indikationen zur UVB-Phototherapie. Dtsch Med Wochenschr 132: 888–891PubMedGoogle Scholar
  177. Schöfer H, Simonsen L (2010): Fusidic acid in dermatology: an updated review. Eur J Dermatol 20: 6–15PubMedGoogle Scholar
  178. Schülke & Mayr GmbH (2011): Octenisept® – Ödematöse Schwellungen und Gewebeschädigungen nach Wundspülungen unter Druck - Warnung vor nicht bestimmungsgemäßem Gebrauch Rote Hand Brief 21. Januar 2011, http://www.akdae.de/Arzneimittelsicherheit/RHB/20110127.pdf
  179. Schulze-Dirks A, Frosch PJ (1988): Kontaktallergie auf Dexpanthenol. Hautarzt 39: 375–377PubMedGoogle Scholar
  180. Shmidt E, Wetter DA, Ferguson SB, Pittelkow MR (2011): Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-a inhibitors: The Mayo Clinic experience, 1998 to 2010. J Am Acad Dermatol 67: e179–185Google Scholar
  181. Sigurgeirsson B, Elewski BE, Rich PA, Opper C, Cai B, Nyirady J, Bakshi R (2006): Intermittent versus continuous terbinafine in the treatment of toenail onychomycosis: A randomaized, double-blind comparison. J Dermatol Treatm 17: 38–44Google Scholar
  182. Singal A, Khanna D (2011): Onychomycosis: Diagnosis and management. Indian J Dermatol Venereol Leprol 77: 659–672PubMedGoogle Scholar
  183. Smith RG (2008): Enzymatic debriding agents: an evaluation of the medical literature. Ostomy Wound Manage 54: 16–34PubMedGoogle Scholar
  184. Solares CA, Batra PS, Hall GS, Citardi MJ (2006): Treatment of chronic rhinosinusitis exacerbations due to methicillin-resistant Staphylococcus aureus with mupirocin irrigations. Am J Otolaryngol 27: 161–165PubMedGoogle Scholar
  185. Stille W, Brodt HR, Groll AH, Just-Nübling G (2005): Antibiotika-Therapie. Klinik und Praxis der antiinfektiösen Behandlung, 11. Auflage. Schattauer, Stuttgart-New YorkGoogle Scholar
  186. Strömberg HE, Ågren MS (1984): Topical zinc oxide treatment improves arterial and venous leg ulcers. Br J Dermatol 111: 461–468PubMedGoogle Scholar
  187. Subissi A, Monti D, Togni G, Mailland F (2010): Ciclopirox: recent nonclinical and clinical data relevant to its use as a topical antimycotic agent. Drugs 70: 2133–2152PubMedGoogle Scholar
  188. Sunderkötter C, Herrmann M, Jappe U (2006): Antimikrobielle Therapie in der Dermatologie. J Dtsch Dermatol Ges 4: 10–26Google Scholar
  189. Sundström A, Alfredsson L, Sjölin-Forsberg G, Gerdén B, Bergman U, Jokinen J (2010): Association of suicide attempts with acne and treatment with isotretinoin: retrospective Swedish cohort study. Br Med J 341: c5812Google Scholar
  190. Sweetser MT, Dawson KT, Bozic C (2013): Manufacturer's response to case reports of PML. N Engl J Med 368: 1659–161Google Scholar
  191. Tadicherla S, Ross K, Shenefelt PD, Fenske NA (2009): Topical corticosteroids in dermatology. J Drugs Dermatol 8: 1093–1105PubMedGoogle Scholar
  192. Tennis P, Gelfand JM, Rothman KJ (2011): Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors. Br J Dermatol 165: 465–473PubMedGoogle Scholar
  193. Thaçi D, Schöfer H (2005): Topische Antibiotika zur Therapie von Hautinfektionen. Hautarzt 56: 381–396Google Scholar
  194. Thaçi D, Weisenseel P, Philipp S, Rosenbach T, Rotterdam S, Augustin M, Neureither M, Reich K (2013): Efficacy and safety of fumaric acid esters in patients with psoriasis on medication for comorbid conditions - a retrospective evaluation (FACTS). J Dtsch Dermatol Ges 11: 429–435PubMedGoogle Scholar
  195. Thielitz A, AbdeL-Naser MB, Fluhr JW, Zouboulis CC, Gollnick H (2010): Topische Retinoide bei Akne – eine evidenzbasierte Übersicht. J Dtsch Dermatol Ges 8 (Suppl 1): S15–23PubMedGoogle Scholar
  196. Udompataikul M, Limpa-o-vart D (2012): Comparative trial of 5% dexpanthenol in water-in-oil formulation with 1% hydrocortisone ointment in the treatment of childhood atopic dermatitis: a pilot study. J Drugs Dermatol 11: 366–374PubMedGoogle Scholar
  197. Uter W, Geier J, Fuchs T (2000): Contact allergy to polidocanol, 1992 to 1999. J All Clin Immunol 106: 1203–1204Google Scholar
  198. Valente Duarte de Sousa IC (2014): Novel pharmacological approaches for the treatment of acne vulgaris. Expert Opin Investig Drugs 2: 1–22Google Scholar
  199. van de Kerkhof PC, Kragballe K, Segaert S, Lebwohl M; International Psoriasis Council (2011): Factors impacting the combination of topical corticosteroid therapies for psoriasis: perspectives from the International Psoriasis Council. J Eur Acad Dermatol Venereol 25: 1130–139PubMedGoogle Scholar
  200. van Oosten BW, Killestein J, Barkhof F, Polman CH, Wattjes MP (2013): PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med 368: 1658–1659PubMedGoogle Scholar
  201. van Steensel MAM (2007): Emerging drugs for ichthyosis. Expert Opin Emerg Drugs 12: 647–656PubMedGoogle Scholar
  202. van Zuuren EJ, Gupta AK, Gover MD, Graber M, Hollis S (2007): Systematic review of rosacea treatments. J Am Acad Dermatol 56: 107–1015Google Scholar
  203. von Krogh G (1978): Topical treatment of penile condylomata acuminata with podophyllin, podophyllotoxin and colchicine. A comparative study. Acta Derm Venereol 58: 163–168.Google Scholar
  204. Walker F, Adamczyk A, Kellerer C, Belge K, Brück J, Berner T, Merten K, Núnez Gómez N, Neureither M, Röcken M, Ghoreschi K; The study group (2014): Fumaderm? in daily practice for psoriasis - dosing, efficacy and quality of life. Br J Dermatol 2014 May 10. doi: 10.1111/bjd.13098. [Epub ahead of print]Google Scholar
  205. Walluf-Blume D (1991): Aufbereitung und Nachzulassung von OTC-Arzneimitteln in den USA 1990. Pharm Ind 53: 152–158Google Scholar
  206. Wananukul S, Limpongsanuruk W, Singalavanija S, Wisuthsarewong W (2006): Comparison of dexpanthenol and zinc oxide ointment with ointment base in the treatment of irritant diaper dermatitis from diarrhea: a multicenter study. J Med Assoc Thai 89: 1654–1658PubMedGoogle Scholar
  207. Warshaw EM, Fett DD, Bloomfield HE, Grill JP, Nelson DB, Quintero V, Carver SM, Zielke GR, Lederle FA (2005): Pulse versus continuous terbinafine for onychomycosis: a randomized, double-blind, controlled study. J Am Acad Dermatol 53: 578–584PubMedGoogle Scholar
  208. Wickline MM (2004): Prevention and treatment of acute radiation dermatitis: a literature review. Oncol Nurs Forum 31: 237–247PubMedGoogle Scholar
  209. Wilkinson JD (1998): Fusidic acid in dermatology. Br J Dermatol 139 (Suppl 53): 37–40PubMedGoogle Scholar
  210. Williams H (2002): New treatments for topic dermatitis. Brit Med J 324: 1533–1534PubMedCentralPubMedGoogle Scholar
  211. Williams HC, Dellavalle RP, Garner S (2012): Acne vulgaris. Lancet 379: 361–372.PubMedGoogle Scholar
  212. Wohlrab J (2006): Basistherapie der Psoriasis vulgaris. Hautarzt 57: 661–665PubMedGoogle Scholar
  213. Wolff HH, Kieser M (2007): Hamamelis in children with skin disorders and skin injuries: results of an observational study. Eur J Pediatr 166: 943–948PubMedGoogle Scholar
  214. Worret WI, Fluhr JW (2006): Acne therapy with topical benzoyl peroxide, antibiotics and azelaic acid. J Dtsch Dermatol Ges 4: 293–300PubMedGoogle Scholar
  215. Wright JB, Lam K, Burrell RE (1998): Wound management in an era of increasing bacterial antibiotic resistance: A role for topical silver treatment. Am J Infect Control 26: 572–577PubMedGoogle Scholar
  216. Yan J, Chen SL, Wang HN, Wu TX (2006): Meta-analysis of 5% imiquimod amd 0,5% podophyllotoxin in the treatment of condylomata acuminata. Dermatology 213: 218–223PubMedGoogle Scholar
  217. Yates JE, Phifer JB, Flake D (2009): Clinical inquiries. Do nonmedicated topicals relieve childhood eczema? J Fam Pract 58: 280–281PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Uwe Fricke
    • 1
  1. 1.Pharmakologisches InstitutUniversität HeidelbergHeidelberg

Personalised recommendations